Incyte Signs a Worldwide License Agreement with MorphoSys for Tafasitamab

Incyte Signs a Worldwide License Agreement with MorphoSys for Tafasitamab

Shots:

  • MorphoSys to receive $750M upfront, an equity investment of $150M in ADS of MorphoSys, up to 1.1B milestones and royalties on sales of Tafasitamab (Ex- US). The companies will jointly commercialize Tafasitamab in the US with equal profit & loss sharing  
  • Incyte will hold exclusive commercialization rights of the product outside the US and will lead the commercialization strategy and book all revenues from sales of Tafasitamab outside the US. Additionally, the companies will share development cost in global and US-based studies @ 55% (Incyte) to 45% (MorphoSys) while Incyte will be wholly responsible for the product development (Ex- the US)
  • Tafasitamab is an investigational humanized Fc-engineered mAb targeting CD19 with the expected FDA’s approval and MAA submission to the EMA of its combination therapy with Lenalidomide for r/r DLBCL in mid- 2020. The companies will codevelop the therapy for DLBCL, FL, MZL and CLL

Click here to­ read full press release/ article | Ref: Morphosys | Image: The Street